Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
17.05 USD | +5.44% | +13.06% | +55.85% |
Apr. 23 | Edgewise Therapeutics Secures Orphan Drug Designations for Sevasemten in EU | MT |
Apr. 22 | RBC Raises Price Target on Edgewise Therapeutics to $32 From $28, Keeps Outperform, Speculative Risk | MT |
Chart calendar Edgewise Therapeutics, Inc.
Upcoming events on Edgewise Therapeutics, Inc.
Past events on Edgewise Therapeutics, Inc.
2024-04-16 01:12 pm | American Academy of Neurology Meeting |
2024-04-16 08:30 am | ARCH EDG-5506 Two Year Topline Study Results |
2024-04-02 02:20 pm | Cantor Fitzgerald Muscular Dystrophy Symposium |
2024-03-11 12:00 pm | Leerink Partners Global Biopharma Conference |
2024-03-06 11:15 am | Muscular Dystrophy Association Clinical & Scientific Conference |
2024-03-03 | Muscular Dystrophy Association Clinical & Scientific Conference - Poster Number: M146 |
2024-03-03 | Muscular Dystrophy Association Clinical & Scientific Conference - Poster Number: M147 |
2024-03-03 | Muscular Dystrophy Association Clinical & Scientific Conference - Poster Number: M145 |
2024-02-22 08:00 am | Q4 2023 Earnings Release |
2024-01-09 01:30 pm | JPMorgan Healthcare Conference |
2023-11-29 08:00 am | Piper Sandler Healthcare Conference |
2023-11-15 10:55 am | Stifel Healthcare Conference |
2023-11-13 02:20 pm | American Heart Association Scientific Meeting |
2023-11-11 11:30 am | American Heart Association Scientific Meeting |
2023-11-09 08:00 am | Q3 2023 Earnings Release |
2023-10-06 02:00 pm | World Muscle Society International Congress - Effects of EDG-5506 |
2023-10-06 02:00 pm | World Muscle Society International Congress - Development of a conceptual |
2023-10-06 02:00 pm | World Muscle Society International Congress - Characterization |
2023-10-03 04:30 pm | Investor Meeting - Key Opinion Leaders |
2023-08-10 08:00 am | Q2 2023 Earnings Release |
Annual results
Fiscal Period | December | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|
Net sales Million USD | Released Forecast Spread | 0,00 | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 |
EBITDA Million USD | Released Forecast Spread | 0,00 | -42,9 -41,7 -2.86% | -71,3 -69,7 -2.29% | -113 -109 -3.28% | -130 |
EBIT Million USD | Released Forecast Spread | 0,00 | -43,2 -42,0 -2.9% | -71,7 -70,4 -1.78% | -114 -111 -3.05% | -141 |
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 0,00 | -42,8 -43,0 0.51% | -67,6 -69,8 3.15% | -100 -97,2 -3.08% | -126 |
Net income Million USD | Released Forecast Spread | -17,1 | -42,8 -43,9 2.39% | -67,6 -69,3 2.43% | -100 -98,3 -1.94% | -131 |
EPS USD | Released Forecast Spread | -0,12 | -1,14 -1,17 2.8% | -1,26 -1,32 4.59% | -1,57 -1,55 -1.46% | -1,76 |
Announcement Date | 05/03/21 | 24/02/22 | 23/02/23 | 22/02/24 | - |
Quarterly results
Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
EBITDA Million USD | Released Forecast Spread | -12,7 -12,9 0.82% | -14,7 -14,0 -5.62% | -16,4 -16,8 2.6% | -18,2 -18,9 4.15% | -22,0 -21,7 -1.35% | -25,5 -23,6 -8.23% | -25,6 | -29,0 -26,4 -9.85% | -33,4 -29,5 -13.09% | -29,3 | -30,5 | -33,9 | -36,4 | |
EBIT Million USD | Released Forecast Spread | -12,8 -11,6 -10.51% | -14,8 -13,8 -7.06% | -16,5 -16,3 -1.22% | -18,3 -18,4 0.87% | -22,1 -20,9 -5.73% | -25,7 -22,7 -13.37% | -25,3 -26,4 4.18% | -29,5 -26,9 -9.34% | -33,9 -30,7 -10.34% | -33,6 | -34,7 | -36,6 | -39,0 | -35,6 |
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -12,7 -13,0 2.15% | -14,7 -13,8 -6.19% | -16,1 -16,9 4.65% | -17,5 -19,0 7.78% | -19,4 -21,7 10.63% | -22,8 -23,6 3.33% | -21,5 -24,5 12.37% | -25,7 -24,5 -4.95% | -30,1 -27,2 -10.96% | -30,1 | -31,0 | -33,3 | -35,1 | -35,6 |
Net income Million USD | Released Forecast Spread | -12,7 -13,8 7.67% | -14,7 -13,9 -5.44% | -16,1 -16,7 3.79% | -17,5 -18,7 6.34% | -19,4 -21,2 8.35% | -22,8 -23,4 2.47% | -21,5 -25,5 15.73% | -25,7 -25,9 0.82% | -30,1 -28,3 -6.61% | -31,4 | -32,5 | -34,7 | -36,5 | -35,6 |
EPS USD | Released Forecast Spread | -0,26 -0,28 6.54% | -0,30 -0,28 -6.19% | -0,32 -0,34 4.95% | -0,34 -0,36 5.15% | -0,31 -0,36 13.24% | -0,36 -0,37 1.94% | -0,34 -0,41 16.42% | -0,41 -0,41 -0.37% | -0,47 -0,44 -5.98% | -0,40 | -0,40 | -0,42 | -0,43 | -0,51 |
Announcement Date | 24/02/22 | 11/05/22 | 04/08/22 | 03/11/22 | 23/02/23 | 11/05/23 | 10/08/23 | 09/11/23 | 22/02/24 | - | - | - | - | - |
2024-04-30 | DYNE THERAPEUTICS, INC.: Q1 2024 Earnings Release (Projected) |
2024-04-30 | PROTAGONIST THERAPEUTICS, INC.: Q1 2024 Earnings Release (Projected) |
2024-04-30 | EDITAS MEDICINE, INC.: Q1 2024 Earnings Release (Projected) |
2024-04-30 | AZENTA, INC.: Q2 2024 Earnings Release (Projected) |
2024-05-01 06:30 am | UNITED THERAPEUTICS CORPORATION: Q1 2024 Earnings Release |
2024-05-01 06:30 am | BIO-TECHNE CORPORATION: Q3 2024 Earnings Release |
2024-05-01 07:00 am | ALKERMES PLC: Q1 2024 Earnings Release |
2024-05-01 | VIR BIOTECHNOLOGY, INC.: Q1 2024 Earnings Release |
2024-05-01 | CELLDEX THERAPEUTICS, INC.: Q1 2024 Earnings Release (Projected) |
2024-05-01 | MIRUM PHARMACEUTICALS, INC.: Q1 2024 Earnings Release (Projected) |
Past sector events for Edgewise Therapeutics, Inc.
Today | CRISPR THERAPEUTICS AG: Q1 2024 Earnings Release (Projected) |
2024-04-29 04:05 pm | QIAGEN N.V.: Q1 2024 Earnings Release |
2024-04-28 | BEIJING SUN-NOVO PHARMACEUTICAL RESEARCH CO., LTD.: Q1 2024 Earnings Release (Projected) |
2024-04-28 | SINO BIOLOGICAL,INC.: Q1 2024 Earnings Release |
2024-04-28 | JOINN LABORATORIES(CHINA)CO.,LTD.: Q1 2024 Earnings Release |
2024-04-28 | MORPHOSYS AG: Q1 2024 Earnings Release |
2024-04-26 | GEMPHARMATECH CO., LTD.: Q1 2024 Earnings Release |
2024-04-26 | GEMPHARMATECH CO., LTD.: Q4 2023 Earnings Release |
2024-04-26 01:00 am | BB BIOTECH AG: Q1 2024 Earnings Release |
2024-04-25 | BIDE PHARMATECH CO., LTD.: Q4 2023 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- EWTX Stock
- Calendar Edgewise Therapeutics, Inc.